Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2.

ABSTRACT:

Background

Neutralizing antibodies (nAbs) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) can play an important role in reducing impacts of the COVID-19 pandemic, complementing ongoing public health efforts such as diagnostics and vaccination. Rapidly designing, manufacturing and distributing nAbs requires significant planning across the product value chain and an understanding of the opportunities, challenges and risks throughout.

Methods

A systems framework comprised of four critical components is presented to aid in developing effective end-to-end nAbs strategies in the context of a pandemic: (1) product design and optimization, (2) epidemiology, (3) demand and (4) supply. Quantitative models are used to estimate product demand using available epidemi

SUBMITTER: Guttieres D 

PROVIDER: S-EPMC8022923 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature